Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) EBITDA: 2009-2025

Historic EBITDA for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to -$1.5 million.

  • Aytu Biopharma's EBITDA fell 61.72% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 274.71%. This contributed to the annual value of -$7.8 million for FY2025, which is 259.20% down from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's EBITDA is -$1.5 million, which was up 80.27% from -$7.6 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's EBITDA peaked at $3.1 million during Q4 2023, and registered a low of -$53.4 million during Q1 2022.
  • Over the past 3 years, Aytu Biopharma's median EBITDA value was -$1.5 million (recorded in 2025), while the average stood at -$1.8 million.
  • In the last 5 years, Aytu Biopharma's EBITDA slumped by 1,792.90% in 2024 and then skyrocketed by 251.60% in 2025.
  • Over the past 5 years, Aytu Biopharma's EBITDA (Quarterly) stood at -$11.3 million in 2021, then skyrocketed by 39.19% to -$6.9 million in 2022, then surged by 145.81% to $3.1 million in 2023, then crashed by 153.88% to -$1.7 million in 2024, then slumped by 61.72% to -$1.5 million in 2025.
  • Its last three reported values are -$1.5 million in Q3 2025, -$7.6 million for Q2 2025, and $2.4 million during Q1 2025.